Eli Lilly To Build $6.5 Billion Houston Plant For Obesity Pill Amid Surging GLP-1 Demand

Eli Lilly will invest $6.5B in a new Houston plant as part of a $27B U.S. expansion. The facility will produce obesity and diabetes drugs, creating thousands of jobs and boosting domestic pharmaceutical output.